🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Discover our innovative framework, built on core values like healthcare access, equity, & sustainability🔄It's an iterative process designed to adapt to evolving healthcare landscapes🔗 Reconciling EU regulations with our vision for accessible healthcare👉access2meds.eu/ascertain-news…

'Als kankerpatiënt ben je afhankelijk van de arts die bepaalde opties heeft om jou te behandelen. Die markt is gewoon heel anders, het is beslist geen vrije markt,' volgens hoogleraar Carin Uyl-de Groot in IKNL eur.nl/eshpm/nieuws/v… Erasmus University #drugpricing ASCERTAIN

#ISPOREurope2023 sessions🌎 ➡️Unveiling the EU-HTA Regulation: A Deep Dive Into the Joint Clinical Assessment ➡️Horizon Europe Project: Supporting a Sustainable & Transparent Legal EU HTA Framework, Accessibility of Innovative Technologies & Health Equity🔗cutt.ly/ewQEcEIo

#ReadingTip📊🔬The European Medicines Agency (EMA) supports pharmaceutical companies through Business Pipeline Meetings (BPMs). An analysis of BPMs in oncology from 2018 to 2022 revealed interesting findings #PharmaceuticalInnovation #OncologyResearch 🔗ascpt.onlinelibrary.wiley.com/doi/full/10.10…

We are proud to be part of the ASCERTAIN project! The pharmacoeconomics team of Gesundheit Österreich takes the lead in developing new approaches for pricing innovative technologies to improve patient access and stimulate entrepreneurship. Learn more 🎓access2meds.eu

🔬📚"Access and Quality of Biomarker Testing for Precision Oncology in Europe". Explore #CancerPrecision in Europe. Key findings: access, funding challenges, NGS use, & quality assurance. Action needed for equal access to innovative therapies🔗cutt.ly/UwEiA4S3 #Healthcare

Let's take actions to make innovative therapies accessible to all. 🌐🩺 #PrecisionMedicine #CancerResearch #Oncology #Cancer

What's a fair price for health technologies? Poster with first findings from a review of fair pricing definitions at #ISPOR ASCERTAIN Gesundheit Österreich

Your input is crucial! Together with ASCERTAIN, EHA is working to improve equitable access to drugs through pricing models and value assessment models addressing the needs of patients, doctors, and payers. Fill in the survey: eha.fyi/ascertain_surv…

"Without a better knowledge on R&D costs, we will never be able to negotiate a 'fair' price for all parties" says Anne Hendrickx. Join her at the #A2MForum this week! 📅 8 December 2023 📍 Brussels The European Public Health Alliance (EPHA)

Join us at the 6th European CAR T-cell Meeting in Valencia! 📅 16 February 2024, 09:40 – 09:45 ➡ Session PS04B Translational II – Focus on European Project & Networks #ASCERTAIN European Hematology Association

Nous avons interviewé .Jean-Pascal Labille de .Solidaris Wallonie sur le juste prix des #médicaments 💊 "Depuis 2015, les dépenses de médicaments sont devenues incontrôlables" 👉L'interview complète: bit.ly/46KuNWP

AIM is participating in the Consortium Meeting ASCERTAIN and is a proud partner of that project.

AIM's Fair Pricing Model is the basis for the ASCERTAIN project and will be taken further.

Kicking off the new year🚀➡ASCERTAIN's third consortium meeting on January 16th and 17th📸Consortium members, stakeholders and Advisory Board representatives worked together to shape our path for the year. #healthtech #accessibility

EU funded project ASCERTAIN , of which MPE is a partner, is in its second year! The Consortium meeting ended yesterday with presentations on the project’s progress, followed by discussions and suggestions from partners and advisory board members access2meds.eu/about-ascertai…

Welcome Yannis Natsis to our Advisory Board! 🌟 "#ASCERTAIN addresses the high #prices of new #treatments, testing European welfare states. Now or never to reflect and prepare," says Yannis. Meet our #AdvisoryBoard: lnkd.in/dUU9hVWC 🌍💙 #HealthcareInnovation

💌 Stay in the loop with the latest advancements in healthcare accessibility and affordability. Subscribe to the #ASCERTAIN newsletter and be the first to know about innovative solutions, research insights, and more! Subscribe now: access2meds.eu/about-ascertai…

"Inequity in access to #treatments is a violation of #humanrights. #ASCERTAIN is crucial to eliminate these inequities," says Peter Kapitein. Meet Peter, founder of Inspire2Live, a global patient advocacy organization🌍 #AdvisoryBoard access2meds.eu/advisory-board/